studies

breast cancer - HR positive, palbociclib based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsPALOMA-3, 2016 0.81 [0.64; 1.03] PENELOPE-B, 2021 0.87 [0.61; 1.24] 0.83[0.68; 1.01]PALOMA-3, 2016, PENELOPE-B, 202120%1,771lownot evaluable iDFSdetailed resultsPENELOPE-B, 2021 0.93 [0.74; 1.17] 0.93[0.74; 1.17]PENELOPE-B, 202110%1,250NAnot evaluable progression or deaths (PFS)detailed resultsFLIPPER, 2021 0.55 [0.36; 0.84] PALOMA-3, 2016 0.42 [0.32; 0.56] 0.46[0.36; 0.59]FLIPPER, 2021, PALOMA-3, 2016210%710lownot evaluable objective responses (ORR)detailed resultsFLIPPER, 2021 2.90 [1.81; 4.64] 2.90[1.81; 4.64]FLIPPER, 202110%189NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-14 00:38 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 4,319,144,356,351,357,352,354,353,358,359 - treatments: 1375,1249,1407,1376,1411

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons